Investors meetings
Category: dates
Transgene to Participate in Upcoming Investor Meetings
Transgene Shares (Euronext Paris: TNG) Eligible for Inclusion in PEA-PME Accounts
Eligibility PEA-PME
Transgene To Participate in the Biomed Forum Investor Conference
BIOMED FORUM
Transgene Announces Financial Calendar for 2025
calendrier 2025
Transgene Reports Business, Pipeline and Financial Update for Q3 2024
Financial Q3 2024
Randomized phase I trial of adjuvant individualized TG4050 vaccine in patients with locally advanced resected HPV-negative head and neck squamous cell carcinoma (HNSCC)
C. Le Tourneau, et al. SITC 2024 Abstract available on the SITC website – Download the abstract and the poster
Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024
SITC 2024
Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Develpment
ProBioGen
TG7010: a Novel Chimeric Oncolytic Poxvirus Encoding IL-12 with Improved Properties for Systemic Delivery
J. Foloppe, et al. IOVC 2024 Abstract available on the IOVC website – Download the abstract and the poster